Current and future HCV therapy: do we still need other anti-HCV drugs?

Area of Science:

• Hepatology and Viral Gastroenterology
• Pharmacological Research
• Clinical Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection eradication significantly improves outcomes for liver disease, including cirrhosis and hepatocellular carcinoma (HCC).
• Antiviral therapy has rapidly evolved from pegylated interferon (PEG-IFN) and ribavirin (RBV) to direct-acting antiviral (DAA) combinations, including IFN-free regimens.
• Current IFN-free regimens offer high sustained virological response (SVR) rates (>90%), shorter treatment durations, improved safety, and broader indications.

Purpose of the Study:

• To review the advancements in HCV antiviral therapy and identify key areas for future research and development.
• To address unresolved issues in HCV treatment, such as suboptimal SVR, specific patient populations, and cost-effectiveness.
• To guide ongoing research towards more effective, accessible, and affordable IFN-free treatment strategies.

Main Methods:

• Review of current literature on HCV antiviral therapies, including PEG-IFN/RBV, IFN-based DAA combinations, and IFN-free DAA regimens.
• Analysis of treatment outcomes, safety profiles, and evolving indications for various therapeutic approaches.
• Identification of priority areas for future pharmacological and clinical research based on existing treatment gaps.

Main Results:

• Significant improvements in SVR rates, safety, and treatment duration with the advent of IFN-free DAA regimens.
• Identification of specific challenges including suboptimal SVR in certain genotypes (e.g., HCV genotype 3), and treatment for patients with cirrhosis (compensated and decompensated).
• High cost of current IFN-free regimens limits universal access and necessitates cost-effectiveness documentation.

Conclusions:

• While current IFN-free regimens are highly effective, further research is crucial for optimizing treatment in specific patient subgroups, particularly those with HCV genotype 3 and cirrhosis.
• Development of standardized or personalized backup strategies for non-responders to IFN-free regimens is needed.
• Addressing the high cost of IFN-free therapies through cost-effectiveness studies and development of more affordable regimens is essential for global HCV eradication efforts.